

**Supplementary Figure Legend**

**Supplementary Figure 1:** Consort diagram of the AtezoTRIBE population.

**Supplementary Figure 2:** Kaplan–Meier curves of progression-free survival according to TILs (panel A), Immunoscore® (panel B), Immunoscore-IC® (panel C) and PD-L1 expression (panel D) in the pMMR population of the AtezoTRIBE study.

**Supplementary Figure 3:** Forest-plot according to TILs, Immunoscore®, Immunoscore-IC® and PD-L1 expression of ORR in the overall population and in pMMR subgroup of the AtezoTRIBE study.

**Supplementary Figure 4:** Kaplan–Meier curves of progression-free survival according to TILs (panel A), Immunoscore® (panel B), Immunoscore-IC® (panel C) and PD-L1 expression (panel D) in the overall population of the AtezoTRIBE study.

**Supplementary Figure 5:** Kaplan–Meier curves of progression-free survival according to TILs (panel A), Immunoscore® (panel B), Immunoscore-IC® (panel C) and PD-L1 expression (panel D) in the overall population treated with FOLFOXIRI/bev of the AtezoTRIBE study.

**Supplementary Figure 6:** Kaplan–Meier curves of progression-free survival and overall survival according to TILs in the overall population (panel A and C) and in the pMMR subgroup (panel B and D) of the TRIBE2 study.